Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41

English version České info

Primate lentivirus nef is required for sustained virus replication in vivo and accelerated progression to AIDS. While exploring the mechanism by which Nef increases the infectivity of cell-free virions, we investigated a functional link between Nef and Env. Since we failed to detect an effect of Nef on the quantity of virion-associated Env, we searched for qualitative changes by examining whether Nef alters HIV-1 sensitivity to agents that target distinct features of Env. Nef conferred as much as 50-fold resistance to 2F5 and 4E10, two potent neutralizing monoclonal antibodies (nAbs) that target the membrane proximal external region (MPER) of TMgp41. In contrast, Nef had no effect on HIV-1 neutralization by MPER-specific nAb Z13e1, by the peptide inhibitor T20, nor by a panel of nAbs and other reagents targeting gp120. Resistance to neutralization by 2F5 and 4E10 was observed with Nef from a diverse range of HIV-1 and SIV isolates, as well as with HIV-1 virions bearing Env from CCR5- and CXCR4-tropic viruses, clade B and C viruses, or primary isolates. Functional analysis of a panel of Nef mutants revealed that this activity requires Nef myristoylation but that it is genetically separable from other Nef functions such as the ability to enhance virus infectivity and to downregulate CD4. Glycosylated-Gag from MoMLV substituted for Nef in conferring resistance to 2F5 and 4E10, indicating that this activity is conserved in a retrovirus that does not encode Nef. Given the reported membrane-dependence of MPER-recognition by 2F5 and 4E10, in contrast to the membrane-independence of Z13e1, the data here is consistent with a model in which Nef alters MPER recognition in the context of the virion membrane. Indeed, Nef and Glycosylated-Gag decreased the efficiency of virion capture by 2F5 and 4E10, but not by other nAbs. These studies demonstrate that Nef protects lentiviruses from one of the most broadly-acting classes of neutralizing antibodies. This newly discovered activity for Nef has important implications for anti-HIV-1 immunity and AIDS pathogenesis.

Vyšlo v časopise: Nef Decreases HIV-1 Sensitivity to Neutralizing Antibodies that Target the Membrane-proximal External Region of TMgp41. PLoS Pathog 7(12): e32767. doi:10.1371/journal.ppat.1002442
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002442

Souhrn

Zdroje

1. KestlerHW3rdRinglerDJMoriKPanicaliDLSehgalPK 1991 Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65 651 662

2. DeaconNJTsykinASolomonASmithKLudford-MentingM 1995 Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 988 991

3. KirchhoffFGreenoughTCBrettlerDBSullivanJLDesrosiersRC 1995 Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332 228 232

4. GarciaJVMillerAD 1991 Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350 508 511

5. AikenCKonnerJLandauNRLenburgMETronoD 1994 Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76 853 864

6. PiguetVGuFFotiMDemaurexNGruenbergJ 1999 Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 97 63 73

7. SchwartzOMarechalVLe GallSLemonnierFHeardJM 1996 Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2 338 342

8. BlagoveshchenskayaADThomasLFeliciangeliSFHungCHThomasG 2002 HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 111 853 866

9. BaurASSawaiETDazinPFantlWJCheng-MayerC 1994 HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1 373 384

10. SchragerJAMarshJW 1999 HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A 96 8167 8172

11. AlexanderLDuZRosenzweigMJungJUDesrosiersRC 1997 A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol 71 6094 6099

12. SimmonsAAluvihareVMcMichaelA 2001 Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14 763 777

13. BellIAshmanCMaughanJHookerECookF 1998 Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) zeta chain leads to TCR down-modulation. J Gen Virol 79 2717 2727

14. MunchJJanardhanAStolteNStahl-HennigCTen HaaftP 2002 T-cell receptor:CD3 down-regulation is a selected in vivo function of simian immunodeficiency virus Nef but is not sufficient for effective viral replication in rhesus macaques. J Virol 76 12360 12364

15. SchindlerMMunchJKutschOLiHSantiagoML 2006 Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125 1055 1067

16. ZhangFWilsonSJLandfordWCVirgenBGregoryD 2009 Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6 54 67

17. JiaBSerra-MorenoRNeidermyerWRahmbergAMackeyJ 2009 Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5 e1000429

18. ChowersMYSpinaCAKwohTJFitchNJRichmanDD 1994 Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 68 2906 2914

19. MillerMDWarmerdamMTGastonIGreeneWCFeinbergMB 1994 The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179 101 113

20. PizzatoM 2010 MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc Natl Acad Sci U S A 107 9364 9369

21. ChowersMYPandoriMWSpinaCARichmanDDGuatelliJC 1995 The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212 451 457

22. AikenCTronoD 1995 Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69 5048 5056

23. GoldsmithMAWarmerdamMTAtchisonREMillerMDGreeneWC 1995 Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 69 4112 4121

24. PandoriMWFitchNJCraigHMRichmanDDSpinaCA 1996 Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 70 4283 4290

25. SchwartzOMarechalVDanosOHeardJM 1995 Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 69 4053 4059

26. CavroisMNeidlemanJYonemotoWFenardDGreeneWC 2004 HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 328 36 44

27. FacklerOTMorisATibroniNGieseSIGlassB 2006 Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 351 322 339

28. LaguetteNBenichouSBasmaciogullariS 2009 Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol 83 1093 1104

29. RoethJFCollinsKL 2006 Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 70 548 563

30. OhnoHAguilarRCFournierMCHenneckeSCossonP 1997 Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 238 305 315

31. BogeMWyssSBonifacinoJSThaliM 1998 A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J Biol Chem 273 15773 15778

32. WyssSBerlioz-TorrentCBogeMBlotGHoningS 2001 The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor. J Virol 75 2982 2992

33. SandrinVCossetFL 2005 Intracellular vs. cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag and the expression of the Nef protein. J Biol Chem 281 528 542

34. PizzatoMHelanderAPopovaECalistriAZamborliniA 2007 Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A 104 6812 6817

35. MoulardMLortat-JacobHMondorIRocaGWyattR 2000 Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74 1948 1960

36. BurtonDRPyatiJKoduriRSharpSJThorntonGB 1994 Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 1024 1027

37. ThaliMMooreJPFurmanCCharlesMHoDD 1993 Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67 3978 3988

38. ChoeHLiWWrightPLVasilievaNVenturiM 2003 Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114 161 170

39. TrkolaAPurtscherMMusterTBallaunCBuchacherA 1996 Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 1100 1108

40. PurtscherMTrkolaAGruberGBuchacherAPredlR 1994 A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10 1651 1658

41. StieglerGKunertRPurtscherMWolbankSVoglauerR 2001 A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17 1757 1765

42. ZwickMBLabrijnAFWangMSpenlehauerCSaphireEO 2001 Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 10892 10905

43. WildCTShugarsDCGreenwellTKMcDanalCBMatthewsTJ 1994 Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91 9770 9774

44. ArganarazERSchindlerMKirchhoffFCortesMJLamaJ 2003 Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem 278 33912 33919

45. LamaJMangasarianATronoD 1999 Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 9 622 631

46. DragicTLitwinVAllawayGPMartinSRHuangY 1996 HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 667 673

47. ParrenPWWangMTrkolaABinleyJMPurtscherM 1998 Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol 72 10270 10274

48. ZhangYJFredrikssonRMcKeatingJAFenyoEM 1997 Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 238 254 264

49. UNAIDS 2010 Global report: UNAIDS report on the global AIDS epidemic 2010. Available: http://www.unaids.org/globalreport/Global_report.htm. Accessed 20 October 2011

50. LiMSalazar-GonzalezJFDerdeynCAMorrisLWilliamsonC 2006 Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80 11776 11790

51. YellinMJLeeJJChessLLedermanS 1991 A human CD4- T cell leukemia subclone with contact-dependent helper function. J Immunol 147 3389 3395

52. SakselaKChengGBaltimoreD 1995 Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. Embo J 14 484 491

53. BresnahanPAYonemotoWFerrellSWilliams-HermanDGeleziunasR 1998 A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol 8 1235 1238

54. CraigHMPandoriMWGuatelliJC 1998 Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci U S A 95 11229 11234

55. GreenbergMDeTulleoLRapoportISkowronskiJKirchhausenT 1998 A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol 8 1239 1242

56. LiuLXHevekerNFacklerOTAroldSLe GallS 2000 Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J Virol 74 5310 5319

57. ZhengYHPlemenitasAFieldingCJPeterlinBM 2003 Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A 100 8460 8465

58. DorfmanTPopovaEPizzatoMGottlingerHG 2002 Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J Virol 76 6857 6862

59. PizzatoMErlweinOBonsallDKayeSMuirD 2009 A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods 156 1 7

60. LanghammerSFiebigUKurthRDennerJ 2005 Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 23 3341 3348

61. FiebigUHartmannMGBannertNKurthRDennerJ 2006 Transspecies transmission of the endogenous koala retrovirus. J Virol 80 5651 5654

62. LanghammerSHubnerJKurthRDennerJ 2006 Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology 117 229 237

63. ChazalNSingerGAikenCHammarskjoldMLRekoshD 2001 Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 75 4014 4018

64. SongLSunZYColemanKEZwickMBGachJS 2009 Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci U S A 106 9057 9062

65. CampbellEMNunezRHopeTJ 2004 Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 78 5745 5755

66. ChakrabartiBKWalkerLMGuenagaJFGhobbehAPoignardP 2011 Direct Antibody Access to the HIV-1 MPER Positively Correlates with Neutralization Sensitivity. J Virol 85 8217 8226

67. RuprechtCRKrarupAReynellLMannAMBrandenbergOF 2011 MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 208 439 454

68. SchibliDJMontelaroRCVogelHJ 2001 The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 40 9570 9578

69. BuzonVNatrajanGSchibliDCampeloFKozlovMM 2010 Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 6 e1000880

70. SunZYOhKJKimMYuJBrusicV 2008 HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28 52 63

71. HaynesBFFlemingJSt ClairEWKatingerHStieglerG 2005 Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 1906 1908

72. Sanchez-MartinezSLorizateMKatingerHKunertRNievaJL 2006 Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 22 998 1006

73. AlamSMMorelliMDennisonSMLiaoHXZhangR 2009 Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 106 20234 20239

74. CardosoRMZwickMBStanfieldRLKunertRBinleyJM 2005 Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 163 173

75. OfekGTangMSamborAKatingerHMascolaJR 2004 Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78 10724 10737

76. DennisonSMStewartSMStempelKCLiaoHXHaynesBF 2009 Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol 83 10211 10223

77. van't WoutABSwainJVSchindlerMRaoUPathmajeyanMS 2005 Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol 79 10053 10058

78. MujawarZTamehiroNGrantASviridovDBukrinskyM 2010 Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation. Biochemistry 49 8338 8349

79. BruggerBKrautkramerETibroniNMunteCERauchS 2007 Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology 4 70

80. MaesoRHuarteNJulienJPKunertRPaiEF 2011 Interaction of Anti-HIV Type 1 Antibody 2F5 with Phospholipid Bilayers and Its Relevance for the Mechanism of Virus Neutralization. AIDS Res Hum Retroviruses 27 863 876

81. Saez-CirionANirSLorizateMAgirreACruzA 2002 Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 277 21776 21785

82. GieseSIWoerzIHomannSTibroniNGeyerM 2006 Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef. Virology 355 175 191

83. WangJKKiyokawaEVerdinETronoD 2000 The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A 97 394 399

84. ZhengYHPlemenitasALinnemannTFacklerOTPeterlinBM 2001 Nef increases infectivity of HIV via lipid rafts. Curr Biol 11 875 879

85. LorizateMBruggerBAkiyamaHGlassBMullerB 2009 Probing HIV-1 membrane liquid order by Laurdan staining reveals producer cell-dependent differences. J Biol Chem 284 22238 22247

86. WuXYangZYLiYHogerkorpCM Schief WR, et al. 2010 Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 856 861

87. WalkerLMPhogatSKChan-HuiPYWagnerDPhungP 2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

88. MonteroMvan HoutenNEWangXScottJK 2008 The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72 54 84, table of contents

89. BianchiEJoyceJGMillerMDFinnefrockACLiangX 2010 Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107 10655 10660

90. BinleyJMLybargerEACrooksETSeamanMSGrayE 2008 Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 11651 11668

91. LiYSvehlaKLouderMKWycuffDPhogatS 2009 Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83 1045 1059

92. VerityEEZotosDWilsonKChatfieldCLawsonVA 2007 Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J Virol 81 9268 9278

93. PizzatoMPopovaEGottlingerHG 2008 Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. J Virol 82 10811 10819

94. MaudruTPedenKW 1998 Adaptation of the fluorogenic 5′-nuclease chemistry to a PCR-based reverse transcriptase assay. Biotechniques 25 972 975

95. AccolaMAStrackBGottlingerHG 2000 Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 74 5395 5402